-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on Immunome, Raises Price Target to $33

Benzinga·11/17/2025 12:59:38
Listen to the news
Stephens & Co. analyst Sudan Loganathan maintains Immunome (NASDAQ:IMNM) with a Overweight and raises the price target from $25 to $33.